Literature DB >> 18301279

Normal-tension glaucoma: is it different from primary open-angle glaucoma?

M Bruce Shields1.   

Abstract

PURPOSE OF REVIEW: Normal-tension glaucoma (NTG) is a common form of open-angle glaucoma throughout the world, and yet there are many unanswered questions regarding both the mechanisms of the optic neuropathy and the treatment of these patients. The present review considers how recent literature advances our understanding of both the mechanisms of glaucomatous damage and the treatment of patients with NTG. RECENT
FINDINGS: The main theme in the current literature continues to be that NTG and primary open-angle glaucoma (POAG) represent a continuum of open-angle glaucomas, in which a certain level of intraocular pressure (IOP) is the predominant causative risk factor in POAG, while additional IOP-independent factors take increasing importance in NTG. There is considerable overlap between the two conditions, however, and within the population of NTG patients there are subsets in which IOP, blood flow and other factors assume relative importance.
SUMMARY: In clinical practice, control of IOP remains the mainstay of managing NTG patients, but consideration must also be given to other factors, especially those that may influence perfusion of the optic nerve head. Treatment paradigms will likely change as researchers continue to investigate the mechanisms of glaucomatous optic neuropathy and search for IOP-independent neuroprotective agents.

Entities:  

Mesh:

Year:  2008        PMID: 18301279     DOI: 10.1097/ICU.0b013e3282f3919b

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  73 in total

1.  Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action.

Authors:  Grace C Shih; David J Calkins
Journal:  Expert Rev Ophthalmol       Date:  2012-04

Review 2.  Neurodegeneration in glaucoma: progression and calcium-dependent intracellular mechanisms.

Authors:  S D Crish; D J Calkins
Journal:  Neuroscience       Date:  2010-12-25       Impact factor: 3.590

3.  Combination medical treatment for primary open angle glaucoma and ocular hypertension: a network meta-analysis.

Authors:  Manuele Michelessi; Kristina Lindsley; Tsung Yu; Tianjing Li
Journal:  Cochrane Database Syst Rev       Date:  2014-11

Review 4.  Critical pathogenic events underlying progression of neurodegeneration in glaucoma.

Authors:  David J Calkins
Journal:  Prog Retin Eye Res       Date:  2012-08-01       Impact factor: 21.198

5.  Prevalence of glaucoma in patients with moderate to severe obstructive sleep apnea: ocular morbidity and outcomes in a 3 year follow-up study.

Authors:  S P Hashim; F A Al Mansouri; M Farouk; A A Al Hashemi; R Singh
Journal:  Eye (Lond)       Date:  2014-08-15       Impact factor: 3.775

6.  Metal chelator combined with permeability enhancer ameliorates oxidative stress-associated neurodegeneration in rat eyes with elevated intraocular pressure.

Authors:  P Liu; M Zhang; M Shoeb; D Hogan; Luosheng Tang; M F Syed; C Z Wang; G A Campbell; N H Ansari
Journal:  Free Radic Biol Med       Date:  2014-02-06       Impact factor: 7.376

Review 7.  Monitoring Neurodegeneration in Glaucoma: Therapeutic Implications.

Authors:  Norimitsu Ban; Carla J Siegfried; Rajendra S Apte
Journal:  Trends Mol Med       Date:  2017-12-07       Impact factor: 11.951

8.  Western blot patterns of serum autoantibodies against optic nerve antigens in dogs with goniodysgenesis-related glaucoma.

Authors:  Stephanie A Pumphrey; Stefano Pizzirani; Christopher G Pirie; M Sawkat Anwer; Tanya Logvinenko
Journal:  Am J Vet Res       Date:  2013-04       Impact factor: 1.156

9.  Reduced-serum vitamin C and increased uric acid levels in normal-tension glaucoma.

Authors:  Kenya Yuki; Dogru Murat; Itaru Kimura; Yuichiro Ohtake; Kazuo Tsubota
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-09-08       Impact factor: 3.117

10.  Laser refractive surgery in glaucoma patients.

Authors:  Essam Osman
Journal:  Saudi J Ophthalmol       Date:  2010-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.